Johnson & Johnson (JNJ)
NYSE:JNJ
Want to see JNJ full AI Analyst Report?
JNJ Stock Chart & Stats
$234.18
-$4.08(-2.79%)
At close: 4:00 PM EST
$234.18
-$4.08(-2.79%)
Day’s Range― - ―
52-Week Range$149.04 - $251.71
Previous CloseN/A
Volume3.80M
Average Volume (3M)7.67M
Market Cap
$556.77B
Enterprise Value$551.36B
Total Cash (Recent Filing)$22.05B
Total Debt (Recent Filing)$17.46B
Price to Earnings (P/E)26.8
Beta0.04
Next Earnings
Jul 15, 2026EPS Estimate
2.85Next Dividend Ex-DateN/A
Dividend Yield2.5%
Share Statistics
EPS (TTM)8.67
Shares Outstanding2,407,217,000
10 Day Avg. Volume7,667,342
30 Day Avg. Volume7,665,473
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)6.18
Price to Sales (P/S)5.35
P/FCF Ratio25.59
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue5.72
Enterprise Value/Gross Profit8.28
Enterprise Value/Ebitda17.44
Forecast
1Y Price Target
$266.40Price Target Upside13.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)11.58
Revenue Forecast (FY)$100.89B
Bulls Say, Bears Say
Bulls Say
Diversified, High-scale Product PortfolioJohnson & Johnson's breadth — dozens of billion-dollar platforms across oncology, immunology and MedTech — creates durable revenue diversification. Reliance is spread across multiple franchises and geographies, reducing single-product risk and supporting steadier multi-year growth and reinvestment.
High And Sustainable ProfitabilityConsistently elevated margins indicate strong pricing power, differentiated products and operational scale. High profitability supports ongoing R&D, manufacturing investments, dividends and share repurchases, underpinning long-term cash generation and strategic flexibility over multiple quarters.
Robust Pipeline And Regulatory ProgressRegulatory momentum (priority review) and recent successful launches signal real pipeline progress in immunology and oncology. New approvals and fast regulatory paths materially expand future addressable markets and can create multi-year revenue streams, offsetting legacy product declines.
Bears Say
Material STELARA ErosionA steep, sustained decline from biosimilars and new-class adoption represents a structural revenue loss in immunology. Replacing multi‑year revenue gaps requires successful launches and uptake; until then, growth and margin profiles remain exposed to this durable headwind.
Margin Deleverage From Launches And MixHeavier launch investments and an unfavorable product mix have materially compressed margins. This type of deleverage can persist for several quarters as commercialization ramps, reducing near-term free cash flow and forcing tradeoffs between growth investment and margin restoration.
Weaker Cash‑flow Momentum & Conversion VariabilityAbsolute cash generation is strong, but declining free cash flow and low operating‑cash conversion point to timing or working‑capital volatility. Less consistent cash conversion reduces predictability for capital allocation and can constrain buybacks, dividends or added investment without raising leverage.
Johnson & Johnson News
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $149.04 and its highest was $251.71 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $556.77B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jul 15, 2026 which is in 46 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Apr 14, 2026. The company reported $2.7 earnings per share for the quarter, beating the consensus estimate of $2.677 by $0.023.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 2.5%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.85.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,407,217,000 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.7 in its last earnings report, beating expectations of $2.677. Following the earnings report the stock price went up 0.899%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in JNJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$266.40 (13.76% Upside)
$266.40 (13.76% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 525.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.52%
12-Months-Change
Fundamentals
Return on Equity
26.26%
Trailing 12-Months
Asset Growth
3.73%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
JNJ Company Deck
JNJ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive commercial and pipeline story: strong top-line operational growth, multiple high-growth products (DARZALEX, CARVYKTI, TECVAYLI, TALVEY, RYBREVANT, TREMFYA) and successful new launches (ICOTYDE, INLEXZO) with raised full‑year guidance and clear long‑term targets (line of sight to double‑digit growth by decade end). Offsetting these positives were significant short‑term headwinds—most notably a steep STELARA decline, GAAP EPS volatility driven by prior-year one‑time items, margin deleverage from heavier launch investments and a soft Q1 free cash flow run‑rate. Management emphasized confidence in recovery/acceleration through the year, substantial R&D and manufacturing investments, and multiple upcoming catalysts, leading to an overall constructive outlook despite near‑term profitability and comparability pressures.View all JNJ earnings summariesJNJ Sales Breakdown
64.12% Innovative Medicine
35.88% MedTech
JNJ Stock 12 Month Forecast
Average Price Target
$266.40
▲(13.76% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
18.83% Mutual Funds
13.91% Other Institutional Investors
43.66% Public Companies and Individual Investors